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Abstract
Many tumors have highly rearranged genomes, but a major unknown is the relative importance and timing of genome
rearrangements compared to sequence-level mutation. Chromosome instability might arise early, be a late event
contributing little to cancer development, or happen as a single catastrophic event. Another unknown is which of the point
mutations and rearrangements are selected. To address these questions we show, using the breast cancer cell line HCC1187
as a model, that we can reconstruct the likely history of a breast cancer genome. We assembled probably the most
complete map to date of a cancer genome, by combining molecular cytogenetic analysis with sequence data. In particular,
we assigned most sequence-level mutations to individual chromosomes by sequencing of flow sorted chromosomes. The
parent of origin of each chromosome was assigned from SNP arrays. We were then able to classify most of the mutations as
earlier or later according to whether they occurred before or after a landmark event in the evolution of the genome,
endoreduplication (duplication of its entire genome). Genome rearrangements and sequence-level mutations were fairly
evenly divided earlier and later, suggesting that genetic instability was relatively constant throughout the life of this tumor,
and chromosome instability was not a late event. Mutations that caused chromosome instability would be in the earlier set.
Strikingly, the great majority of inactivating mutations and in-frame gene fusions happened earlier. The non-random timing
of some of the mutations may be evidence that they were selected.
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Introduction
Each individual cancer genome contains an ’archaeological
record’ of the tumor’s history, and recent studies have begun to
infer the order in which mutations have occurred [1,2]. For
example, if a certain class of mutations clusters at a certain time in
tumor evolution, this might suggest that these mutations were
selected at that stage of evolution or that a particular mutation
mechanism was active at that time.
Whole genome sequencing studies have begun to uncover
hundreds of coding mutations and genome rearrangements in
individual tumors but there are only a few frequently mutated
genes and many more infrequent mutations [3]. Most mutations
seem likely to be passenger events (i.e. random mutations
irrelevant to carcinogenesis) and finding the driver events
(mutations that give a selective advantage) amongst them
represents a considerable challenge [3,4]. This task is further
complicated by a major unknown in cancer biology: the relative
importance and timing of genome rearrangements compared to
sequence-level mutation. Some suggest chromosome instability
might arise early and be essential to tumor suppressor loss [5,6].
Alternatively, chromosomal instability might be a late event,
contributing little to cancer development [7,8], or might result
from a single catastrophic event in some cases [9,10].
We address the above questions by considering the evolution of
the highly mutated genome of HCC1187 [11]. This triple-
negative–i.e. ER-negative, PR-negative, HER2 non-amplified–
ductal breast carcinoma cell line is, from a genomics perspective,
one of the most intensively studied models of breast cancer as
previous studies have examined its genome by whole exome
mutation screening, molecular cytogenetics, massively parallel
paired end sequencing and transcriptome sequencing [3,12–15].
The majority of breast tumors follow a characteristic path of
karyotype evolution, in which successive unbalanced chromosome
translocations and chromosome losses each reduce the chromo-
some number by one – termed ‘monosomic evolution’ (Fig. 1)
[16,17]. About one-third of the cancers, like many human cancers,
undergo endoreduplication (duplication of the entire karyotype) at
some point during this process [17,18]. As a result, these tumors
typically have 65–75 chromosomes at surgery [17]. We show that
HCC1187 is one such tumor and we used its endoreduplication as
PLOS ONE | www.plosone.org 1 June 2013 | Volume 8 | Issue 6 | e64991
an evolutionary landmark around which we could investigate the
timing of different classes of mutation.
Results
Mutations in the HCC1187 Genome
We assembled a list of all known sequence-level mutations in the
HCC1187 genome (Table S6 in File S2). Non-synonymous
coding-sequence mutations were compiled from the coding
sequence screen of Wood et al [3] and other, targeted, re-
sequencing studies [19]. In total, there are 85 known sequence-
level mutations, comprising 75 base substitutions and 10 indels.
Structural mutations, i.e. translocations, inversions, duplications
and deletions, and the resulting fused or interrupted genes, were
compiled by combining our previous analysis of the karyotype
[12,13] with SNP6 array-CGH copy number data [20] and
massively parallel paired-end sequencing [14] (Tables S4, S5 in
File S2).
Our previous analysis had identified the breakpoints of
chromosome rearrangements larger than about 3 Mb [12], and
mapped all balanced breakpoints to gene level, but many
unbalanced rearrangements had been mapped only to 1 Mb
resolution. SNP6 array data allowed us to map these unbalanced
breakpoints more precisely, to around 10 kb resolution, and detect
deletions of less than 3 Mb. Paired end sequencing data identified
the junctions of around 40 percent of the known rearrangements
to sequence level.
Smaller-scale rearrangements, below the resolution of our
previous analysis, were also apparent in the SNP6 array data–13
small deletions ranging from 0.26 kb to 2.3 Mb with a median size
of 257 kb were predicted. There were also 24 small duplications
ranging from 11.7 kb to 2.8 Mb, median size 320 kb. All of these
duplications and deletions were absent in the matched normal
lymphoblastoid cell line, HCC1187BL. Many of these features
were likely to be small interstitial deletions or ‘‘head to tail’’
tandem duplications. Indeed, five of the 13 deletions and 17 of the
24 duplications were confirmed by structural variants detected by
the paired-end sequencing [14]. We identified broken genes and
possible gene fusions for all these additional structural changes
(Tables S1–S6 in File S2). (Paired end sequencing also uncovered
further apparent structural variations that were below the
resolution of SNP6 segmentation [14]. These were not included
in the present analysis, though we checked that they predicted no
additional fusion genes).
These structural rearrangements gave rise to at least twelve
expressed fusion transcripts, confirmed by RT-PCR and Sanger
sequencing: RGS22-SYCP1, CTAGE5-SIP1, PLXND1-TMCC1,
SEC22B-NOTCH2, KLK5-CDH23, BC041478-EXOSC10, AG-
PAT5-MCPH1, SUSD1-ROD1/PTBP3, SGK1-SLC2A12, RHOJ-
SYNE2, PUM1-TRERF1 and CTCF-SCUBE2, some of which have
been reported previously ([12–15] and Table S4 in File S2). Of
these twelve, the first four were predicted to form an in-frame
fusion product.
HCC1187 Endoreduplicated during its History
The HCC1187 karyotype is hypotriploid and highly rear-
ranged, like most breast cancers. The karyotype is highly likely to
have evolved via successive chromosome loss, unbalanced
translocation and endoreduplication, since this is the predominant
pattern in breast tumors (Fig. 1) [17]. We therefore looked for signs
of endoreduplication.
The main evidence that endoreduplication had occurred was
that a high proportion of the genome had been duplicated
precisely once. To make this clearer, we worked out which
chromosome segments derived from which parent by analysing
how many copies of each genomic segment had the same alleles,
using SNP array data (Fig. S1 in File S1). We were able to assign
almost all chromosome segments in the karyotype to one or the
other allelotype (Fig. 2). This showed that many chromosome
segments were present in two copies of the same parental origin,
and most of the remainder appear to have evolved from a pair of
copies (Fig. 2B). For example, all segments of chromosomes 6 and
7 are present in two copies, while there are two complete copies of
chromosome 16 derived from the same parent, one of which has
been split by a balanced translocation.
Inferring the Genome State before Endoreduplication
Having clear evidence that endoreduplication had occurred in
HCC1187, we were able to infer the state of the genome
immediately before it doubled (Fig. 3). To do this, we assumed
that the simplest possible sequence of events had happened, in
particular that endoreduplication accounted for almost all
Figure 1. The ‘Monosomic’ pattern of karyotype evolution followed by most breast tumors, with endoreduplication. A) and B) In the
monosomic pattern of evolution [16,17], each unbalanced translocation reduces the chromosome number by one, and leaves regions of loss of
heterozygosity (LOH). C) Often, at some point, endoreduplication occurs, i.e. the whole chromosome complement doubles, to give a duplicated
translocation and pairs of chromosome segments showing regions of loss of heterozygosity (dashed boxes). The process may then continue with
more unbalanced translocations.
doi:10.1371/journal.pone.0064991.g001
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duplications. The resulting picture of the likely history of the
karyotype almost exactly fits the suggested monosomic pattern
of evolution (Fig. 1), with each unbalanced translocation leading
to loss of one chromosome, plus some whole-chromosome
losses.
We next determined whether the somatic mutations most likely
occurred before or after endoreduplication. As most loci in this
genome had duplicated only once we could infer whether a
mutation happened before or after endoreduplication: if the
mutation occurred before, it would be present in two copies after
the duplication, whereas if the mutation occurred after endor-
eduplication, it would only be present on one of two copies. This
classification would be wrong if gene conversion had occurred, i.e.
copying of an allele from one chromosome to another, but all of
the 83 sequence-level mutations analysed below were found on
only one parent of origin, implying that gene conversion was rare
or absent in this cell line, as is typical for epithelial cancers [21,22].
We placed each structural mutation before or after endoredu-
plication, according to whether the translocation junction or
deletion was duplicated, or involved only one copy of a pair of
participating chromosomes (Figs. 2 and 3). For the three regions of
the genome that were triplicated we assumed that one duplication
had occurred at endoreduplication and another had occurred
later. We determined the copy number of gene fusions, and
confirmed their chromosomal location by fluorescence in situ
hybridization (FISH) (not shown). For small deletions and
duplications, we determined the copy number of the relevant
region relative to flanking regions from array CGH segmentation
to assess whether the segment bearing the deletion or duplication
had itself been duplicated. Earlier deletions and duplication
showed a copy number shift of two or more whereas later events
had a copy number shift of only one.
Seven of the twelve fusion transcripts were classified as before
endoreduplication; two, CTCF-SCUBE2 and BC041478-EXOSC10
were classified later. AGPAT5-MCPH1 and SUSD1-ROD1/PTBP3
and KLK5-CDH23 were undetermined, as their allelic copy
number could not be resolved by array CGH or FISH. We were
able to place seven deletions earlier, and these were all the
homozygous deletions. Five deletions, all heterozygous, were
placed later, with one undetermined. We could unambiguously
Figure 2. The structure of the HCC1187 genome. A) Spectral
karyotype as in [44]. Chromosomes are named A-Z and a-k based on
their relative sizes as in [12]. Cytogenetic description of the karyotype is
in Table S1 in File S2. B) Circos plot [45] of the HCC1187 genome:
Chromosome ideograms around the outside, oriented clockwise pter to
qter. Moving inward, the pale grey and dark grey boxes are
chromosome segments observed by array painting [12] with their
chromosome of origin indicated. Their parent of origin (light grey and
dark grey) was deduced from the number of allelotypes given by
PICNIC segmentation (Fig. S1 in File S1). Note that assignment of
parents 1 and 2 does not transfer between chromosomes. Dark blue
line, total copy number, equivalent to array CGH, from PICNIC. Red line,
copy number of the minor allele; where this is zero, the genome is
homozygous. Chromosome segments that share a translocation break-
point were assumed to have the same parental origin. Inner links
represent interchromosome translocations identified previously [12–
14].
doi:10.1371/journal.pone.0064991.g002
Figure 3. Chromosome segments in HCC1187 and their most
probable state before endoreduplication. Chromosome ideo-
grams are drawn around the outside as in Fig. 2. Outer rings are array
painting segments as in Fig. 2. Inner rings are chromosome segments
that must have been present before endoreduplication. Coloured
circles are different types of mutations, on the outer chromosome
segment on which they were observed: truncating (red), non-
synonymous (blue), small deletion (yellow), small duplication (black),
expressed gene fusion (light blue). Mutations that were on two copies
of a chromosome segment probably occurred before endoreduplica-
tion and are also shown on the inner, pre-endoreduplication genome.
Dashed grey boxes on chromosome 1 and 11 indicate regions where
parental origin was undetermined, because PICNIC segmentation
suggested additional rearrangements had taken place.
doi:10.1371/journal.pone.0064991.g003
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place 14 small duplications relative to endoreduplication: seven
earlier and seven later.
To assign point mutations to one or two copies of particular
chromosomes, we isolated the individual chromosomes in a cell
sorter and re-sequenced the mutated exons (Fig. 4). We confirmed
this analysis for selected genes by measuring the relative number of
mutant and wild-type copies using pyrosequencing (Fig. S2 in File
S1). We were able to place 75 of the 85 previously described
sequence-level mutations before or after endoreduplication, with
only 10 undetermined. Of these ten, two were on a chromosome
that was too small to be resolved in flow sorting, and 8 were not
possible to score, either because they were found on single-copy
genome segments, or they were found in a region where parent of
origin could not be determined. Two reported mutations, in
ZNF674 and HUWE1, were not found in our sample, therefore
presumably occurred in other stocks of the line. They could
therefore be classified as later (Fig. 3, Table 1 and Table S6 in File
S2).
Earlier and Later Mutations
Overall, the proportion of mutations classified as occurring
before endoreduplication (earlier) was fairly similar for structural
and point mutations (Table 1): 27/48 (56%) of structural changes
(translocations, deletions and duplications) and 34/75 (45%)
sequence-level changes were classed as earlier (Fig. 3 and Tables
S4–S7 in File S2).
Among the structural mutations that could be classified, 13/22
(59%) of chromosome translocations were in the earlier group,
while 7/14 (50%) of small duplications were earlier and 7/12
(58%) of small deletions were earlier. For fusion genes, 7/9 (78%)
were classified earlier and, interestingly, all three in-frame fusion
transcripts that could be classified were classified as earlier.
Of the classifiable sequence-level mutations, 58 were missense
mutations, of which 23/58 (40%) fell early. To try to uncover
‘driver’ mutations within this group, we applied the Sorting
Intolerant from Tolerant (SIFT) algorithm [23] to all of the point
mutations, 47 of which could be scored by this method. Of the
missense mutations predicted to be non-functional (tolerated) and
so more likely to be random, 9/28 (32%) were earlier, while 7/19
(37%) mutations predicted to be functional (deleterious) were
earlier (Table 1, Table S6 in File S2). Wood et al. [3] also identified
genes likely to be drivers as ‘candidate cancer genes’ (CAN) based
on their mutation rate and several other bioinformatic estimates of
functionality [3]. The nine CAN genes showed a bias towards the
earlier category, six classified earlier (INHBE, KIAA0427/CTIF,
MYH9, PCDHB15, RNU3IP2/RRP9, TP53) and three in the later
category (ABCB8, KIAA0934/DIP2C, NCB5OR/CYB5R4).
Strikingly different from the overall distribution of mutations in
HCC1187 was the proportion of sequence-level truncation
mutations in earlier rather than later categories: All eight
classifiable INDEL mutations happened earlier, and combining
this figure with nonsense mutations showed 11/13 (85%) protein
truncating mutations happened earlier. This difference in propor-
tion (11/13 truncating vs. 23/58 missense) is statistically significant
(p,0.01 for chi-squared test with continuity correction).
Non-random Timing of Mutation Subsets
The distribution of mutations between earlier and later could
uncover selective pressure for a mutation to occur at a particular
stage in tumor development, or a change in the level of genetic
instability. We therefore estimated the number of random and
non-randomly timed mutations given the proportions of different
mutation classes above.
We used a statistical model to estimate the number of mutations
that showed non-random timing. The model assumed that any
given class of mutations is a mixture of non-random mutations that
must happen earlier (that is, before endoreduplication) and
randomly timed mutations that can happen earlier or later. The
randomly timed mutations are classified as earlier with probability
p and later with probability 1-p, independently for each such
mutation. We find the most likely number, n, of non-randomly
timed mutations (the maximum likelihood estimate, or MLE) and
its 95 percent lower confidence bound, given an estimate of p.
Further details of the model may be found in File S3.
Estimates of p based on total missense mutations or those
predicted to be non-functional (see Table 1) are 0.40 ( = 23/58) or
0.32 ( = 9/28), respectively, and a plausible upper bound would be
0.59 ( = 13/22), the proportion of earlier chromosome transloca-
tions.
Most classes of mutation, including non-synonymous point
mutations, chromosome translocations, duplications, deletions,
predicted functional mutations and CAN genes did not show any
excess of mutation earlier or later. However, the observed
proportion of truncating mutations falling earlier (11/13) suggests
that n .0. When p =0.4, the MLE is n=10 mutations that had to
happen before endoreduplication, with a lower confidence bound
of 6 (File S3) [24]. For p=0.32 n=10, lower bound 7. Thus our
simple statistical model suggests that a number of the truncating
mutations had to occur before endoreduplication.
When we use the high estimate for p, p=0.59, the MLE was
n = 9, but the lower confidence bound is 0, so data from more
tumors would be required.
Discussion
We present one of the most complete studies of any cancer
genome to date, combining the coding sequence scan of Wood
et al [3] with molecular cytogenetic analysis of genome rearrange-
ment. We were able to deduce for most of the mutations and
genome rearrangements whether they most likely occurred before
or after endoreduplication of the genome, giving us a picture of the
pattern of mutation before and after this time point, for this case.
Such detailed analysis was limited to a single cell line as this was
the only example so far of a breast cancer cell line for which there
is rather complete coding sequence data, cytogenetic data and
evidence of endoreduplication, but it serves to demonstrate the
feasibility and potential interest of the approach.
The Earlier Versus Later Classification
Endoreduplication in HCC1187 proved to be a useful
milestone, because numbers of structural changes and point
mutations were fairly equally distributed between the earlier and
later categories, implying that endoreduplication occurred 32–
60% of the way through the mutational history of this genome.
Interpretation of mutation timing depends on the accuracy of
our earlier and later classification of mutations. We were confident
that the tumor had undergone endoreduplication as it showed two
characteristic signatures of this phenomenon: multiple duplicated
rearrangements and multiple duplicated homozygous regions
(Fig. 2). Given that there had been an endoreduplication, we
reconstructed the main steps of HCC1187 karyotype evolution by
assuming that the simplest possible sequence of events had
happened. Implicit was the assumption that, as far as possible,
all duplications had occurred at endoreduplication. The deduced
sequence of chromosome changes (Fig. 3) was consistent with
monosomic evolution (Fig. 1). Three duplications could not be
explained by endoreduplication: these were three chromosome
Timing of Mutations in a Breast Cancer Genome
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segments of the same parental origin that were present in three
copies. The simplest route to these triplications was via endor-
eduplication followed by an additional single-chromosome dupli-
cation.
A few steps in the evolution may have been more complex, but
this would not have altered the earlier versus later classification
very often. Specifically, if all three triplicated chromosomes had
taken a more complex evolutionary route (perhaps duplication
followed by endoreduplication, followed by loss), the classification
of no more than three point mutations could be affected, moving
them from the later category to the ‘undetermined’ class.
Some mutations were omitted from analysis. These were from
the complex regions of 10 p and 11 q where the parent of origin
could not be determined. The omitted mutations comprised eight
non-synonymous missense and two truncating mutations. Even if
we consider the most unfavorable case, that the two truncating
mutations were classified as later, the MLE for the number of non-
random truncation mutations in the earlier group is is n =9, with
a 95% lower bound of 3 when p =0.4, and n =5 or 6 with a 95%
lower bound of 0 when p =0.59.
Timing of Genetic Instability and Other Functions
This earlier versus later classification may help us to understand
a variety of issues including the timing and origins of chromosome
instability and the drivers versus passengers problem for this
particular tumor.
There has been much discussion of when chromosomal
instability occurs, for example some have suggested it as a key
facilitator of early tumorigenesis, notably causing loss of hetero-
zygosity of APC in colorectal cancers [21]. In contrast, some
suggest that the extensive rearrangements of carcinoma karyotypes
might be late progression events [7,8]. Others favor a transient
period of chromosome instability, either at ‘crisis’ caused by
telomere loss, or at some other catastrophic event such as
‘chromothripsis’, in which one or more chromosomes undergo
massive rearrangement, apparently in a single event [9,10].
We observed roughly equal ratios of structural to sequence-level
mutations earlier and later. Although there are other possibilities,
a reasonable explanation is that both mutational processes were
happening at approximately the same rate for much of the
evolution of the tumour. We did not see, for example, a much
higher ratio of rearrangements to point mutations in the earlier
Figure 4. Point mutations on chromosome 6, and whether they occurred before or after endoreduplication. A) Deducing the parental
origin of chromosome 6 segments: the simplest explanation for the allele combinations (blue and red lines on the aCGH plot) in terms of parental
origin. Both copies of chromosome 6 I (chromosome 6 fragments are designated 6 I, 6A, 6D as in ref. [12]) originate from parent 1 and the
chromosome 6 segments of 6A and 6D originate from parent 2. Several small copy number steps are omitted for clarity. B) Sequence traces show
whether mutations are on each isolated chromosome. HSD17B8: Chromosome 6I (2 copies) homozygous G.T mutation (black arrow); chromosome
6A and 6D, no mutation. NCB5OR: Chromosome 6, heterozygous mutant (black arrow). C) The likely evolution of the segments of chromosome 6:
unbalanced translocation of one copy of chromosome 6 was followed by duplication of both chromosomes during endoreduplication. HSD17B8 was
mutated on each copy of chromosome 6I, but not on 6A or 6D, while NCB5OR/CYB5R4 was mutated on only one copy of chromosome 6I. The pre-
endoreduplication state was likely to be one normal copy of chromosome 6 with the other having a mutation in HSD17B8 and having suffered
unbalanced translocation. The NCB5OR/CYB5R4 mutation occurred after endoreduplication.
doi:10.1371/journal.pone.0064991.g004
Table 1. Summary of Mutations in HCC1187 and their timing.
Total Reported Total Classifiable Unclassifiable Earlier Later % Earlier
All Mutations 144 123 21 61 62 50
All Structural mutations 59 48 11 27 21 56
Translocation 22 22 0 13 9 59
Deletion (,2 Mb) 13 12 1 7 5 58
Duplication (,2 Mb) 24 14 10 7 7 50
All Sequence-level mutations 85 75 10 34 41 45
Synonymousa 4 4 0 0 4 0
Missense 66 58 8 23 35 40
Nonsense 5 5 0 3 2 60
INDEL 10 8 2 8 0 100
Mutation Classification
Nonsense and INDEL mutations 15 13 2 11 2 85
Missense classifiable by SIFT 52 47 5 16 31 34
SIFT non-functional 30 28 2 9 19 32
SIFT Functional 22 19 3 7 12 37
CAN genes 9 9 0 6 3 67
Expressed fusion transcripts 12 9 3 7 2 77
In-frame transcriptb 4 3 0 3 0 100
Out of Frame transcriptb 8 6 2 4 2 67
aFew synonymous mutations are known since they were not reported in the main survey of point mutations [3].
bIn-frame and out-of-frame expressed fusion transcripts.
doi:10.1371/journal.pone.0064991.t001
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class, as expected if most of the rearrangements had occurred
during a telomere crisis before endoreduplication.
An important value of the classification is that mutations that
may cause ongoing chromosome instability must generally be in
the ‘earlier’ group as, by definition, they must pre-date almost all
chromosome changes, which were quite numerous before
endoreduplication. Among the mutated genes that might contrib-
ute to chromosome instability were TP53, BAP1 and PAXIP1, and
all were indeed classified as earlier. BAP1/UCHL2 (BRCA1-
associated protein1/ubiquitin carboxy-terminal hydrolase 2) was
discovered as a binding partner of BRCA1 and appears to
participate in the DNA damage response by interacting with
BRCA1 and BARD1 [25;26]. It is a deubiquitinase that controls
ubiquitination of Histone H2A, and is also a component of the
Polycomb repressive deubiquitinase (PR-DUB) complex. Inacti-
vating mutations of BAP1 have been found particularly in uveal
melanomas [27], and as germline mutations that predispose to
melanoma [28] and other cancers. Based on this, Stephens et al.
[29] identified BAP1 mutations as likely driver mutations in breast
cancer. PAXIP1 also seems to be part of the DNA damage
signalling system, interacting through its multiple BRCT domains
[30]. (Another gene relevant to genetic instability, but at the
sequence level, was HUWE1, but we did not find the reported
HUWE1 mutation in our stock. HUWE1 is implicated in base
excision repair according to the UniProt database).
We also considered how other functions relevant to breast
cancer might relate to timing, using the Entrez and Gene
Ontology databases (Table S7 in File S2). Although we do not
know which mutations were driver mutations, a gene involved in
steroid hormone synthesis, HSD17B8, was mutated earlier, while
genes encoding covalent modifiers of histones (HUWE1, IPO7,
MLL4, PAXIP1, PRKAA2) were, except for PAXIP1, mutated later.
Some of these histone modifiers might affect differentiation, while
PAXIP1 might affect genome stability. However, other functional
groupings were less informative: 17 of the genes mutated in
HCC1187 were associated with actin and the cortical cytoskeleton
or integrin signalling–functions highlighted in a study of triple-
negative breast cancers [31] (HCC1187 is triple-negative)–but
they were fairly evenly divided between earlier and later. Similarly
the many genes associated with G-protein coupled receptors and
Rho signalling, and genes associated with apoptosis, were fairly
evenly divided.
Timing and Evidence for Selection
A non-random distribution of mutations between earlier and
later categories could be evidence that a substantial number of
mutations were drivers rather than passengers. The group of
mutations showing greatest deviation from the typical pattern of
around 40% earlier was the truncating mutations (and especially
indels). A non-random distribution could be explained in two
ways: i) the rate of indel mutations was high before endoreduplica-
tion and low after, relative to most other types of mutation ii)
passenger indels accumulated in the same way as other passenger
mutations but more indels accumulated early because they were
selected. We consider (ii) most likely because for 9/11 earlier
truncating mutations, a chromosome loss before endoreduplica-
tion caused loss of the second wild type allele. This is consistent
with chromosome instability facilitating early tumor suppressor
loss, as has been suggested previously [21]. Indeed, the earlier
truncation mutations include known and candidate tumor
suppressor genes TP53, BAP1 (BRCA1-associated protein),
CTNNA1 (CateninA1) and NFKBIA (nuclear factor of kappa light
polypeptide gene enhancer in B-cells inhibitor) [20,29,32–34];
others were AVPI1, GMCL1L/GMCL1P1, GPR81HCAR, MYH9,
SLC4A3, ELP2 and TRIM47.
These data, therefore, support the view that early tumor
suppressor loss is consistent with tumor evolving monosomically
and that driver mutations that cause gene inactivation will be
concentrated pre-endoreduplication. An explanation for this
phenomenon is that loss or inactivation of two alleles pre-
endoreduplication is more likely than loss/inactivation of four
alleles post-endoreduplication [16,17]. Gain of function mutations
are not under the same numerical constraints as tumor suppres-
sors. Where two hits are required to impair tumor suppressor gene
function, only a single mutation is required for oncogenic gains of
function and we might, therefore, see these mutations either side of
endoreduplication. Fusion genes–whose importance in the com-
mon epithelial cancers has only recently been acknowledged
[35,36]– were formed throughout the evolution of this tumor but,
interestingly, the in-frame fusions (most likely to be translated into
functional proteins) were all formed early. Although the numbers
are admittedly too small for statistical certainty, this makes the
early in-frame gene fusions also good candidates for selected
events.
Interpretations of the earlier and later classes depend on when
HCC1187 endoreduplicated. There is some evidence that
endoreduplication occurred in vivo in this case. The original ploidy
of HCC1187 was not reported, only that shortly after its
derivation, HCC1187 had multiple ploidy indices by flow
cytometry [37]. However, around 60 percent of mutations
occurred after endoreduplication. It would be surprising if so
many happened in culture, given that cell lines largely recapitulate
the genomic aberrations observed in primary tumors [38]. If
endoreduplication happened in vitro, only ‘earlier’ mutations
happened in vivo, and all driver mutations will be in the ‘earlier’
set, whereas if endoreduplication happened in vivo (as is often the
case in breast tumours [17]), some driving mutations will be
present in the ‘later’ group. In either case our estimate of non-
randomly timed mutations remains the same.
Comparison with Mutations in Breast Cancers
To attempt to identify mutations in HCC1187 that are
recurrent or known drivers, and relate this to timing, we compared
sequencing data from breast tumours, both genomic sequencing
data [29,31,39–41] and fusion gene data from transcriptome
sequencing [15,42]. However, this was largely uninformative,
because of the heterogeneity and variability of mutations among
cancer cases, and the still limited amount of data available. For
example, Stephens et al [29] identified 31 genes as targets of driver
mutations in breast cancers, from sequencing of 100 exomes and
comparison with known drivers in other cancers, but the
individual tumours had an average of only 1.7 of these genes
mutated, 1.3 if TP53 is excluded. Unsurprisingly, then, in
HCC1187 only two of these drivers, TP53 and BAP1, were
mutated (both earlier). Similarly, of the genes considered likely
drivers by Shah et al [31] in triple negative breast cancers, only
SYNE2 and TP53 were mutated in HCC1187–SYNE2 is fused, also
earlier. Nevertheless, many other genes mutated in HCC1187 are
mutated or rearranged occasionally in the datasets above, so may
be recurrent at a modest level (Tables S4, S7 in File S2). Several
genes involved in fusions have been reported to be fused or
rearranged in other cases–AGPAT5, NOTCH2, PUM1, SEC22B,
SGK1 and TRERF1 (all early or unclassified), while several are
mutated at sequence level, notably SYNE2. Among the genes in
homozygous deletions (all earlier) with four or more reported
mutations or rearrangements were SCN1A, FBXL20 and MYO9A;
while among the point-mutated genes in HCC1187, apart from
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the known drivers BAP1 and TP53, ones with four or more
reported mutations or rearrangements were CAMTA1, ITIH6/
ITIH5L, LHCGR, SPEN, TP53 and ZNF142 (3 of which were
earlier, 3 later). Many of the other genes have been found mutated
in cancers other than breast, including CTNNA1 and NFKBIA
(both earlier, see above). Others have cancer-relevant functions,
such as steroid hormone synthesis (HSD17B8, earlier), and
covalent modification of histones (HUWE1, IPO7, MLL4, PAXIP1,
PRKAA2, all later except PAXIP1) (Table S7 in File S2).
Applicability to Sequencing Data
Our theoretical framework and statistical methods could be
applied, in a modified form, to sequencing data from other
endoreduplicated cell lines and primary tumours, indeed the idea
of placing mutations before or after a duplication event has already
been exploited [1,18]. Endoreduplication is a common process in
epithelial cancers, estimated to occur in more than 50% of breast
cancers [17,18]. Endoreduplicated genomes can often be identifed
by copy number and allele ratios [18], for example, a large
proportion of a recently-endoreduplicated genome will often be
present either in four copies and heterozygous, or two homozygous
copies (Fig. 4). We relied on flow sorting of chromosomes to
quantify our mutations, but the proportion of mutant and
reference alleles could be deduced, for example, by counting
reads from deep massively-parallel sequencing. Earlier mutations
will usually be homozygous in diploid regions, or account for
approximately 50% of mutant reads in tetraploid regions.
Distinguishing between earlier and later events in large datasets
may help identify genes or pathways that must be mutated earlier
or later in a given tumour type.
Conclusion
In conclusion, we provide evidence that, in this cell line,
chromosome instability and rearrangement was not a late and
irrelevant event, and that the great majority of inactivating
mutations and expressed gene fusions appear to have happened
early, and this suggests that most of them were selected.
Materials and Methods
Cell line HCC1187 was from ATCC and was grown in RPMI
1640 medium containing 10% foetal calf serum. Metaphase
preparations and flow sorting of chromosomes were as described
previously [12]. Flow sorted chromosomes were amplified by
Genomiphi whole genome amplification (GE Healthcare, Bucks,
UK). All flow sorted chromosome fractions were hybridized to
normal metaphases to confirm that they were substantially pure
(not shown).
For sequencing, exons with flanking intronic sequence were
amplified using published primer sequences [3]. Reactions were
performed as above using 25 ng flow-sorted and amplified
chromosomes or HCC1187 whole genomic DNA as a target.
PCR products were cleaned up using Nucleofast 96 PCR cleanup
kit (Clontech, Mountain View, CA) and sequenced in both
directions using the same primers as for amplification with BigDye
v3.1 (Applied Biosystems, Foster City, CA) according to manu-
facturer’s instructions on an ABI 3700 capillary DNA sequencer.
SNP6 data [20] are available online (www.sanger.ac.uk/cgi-
bin/genetics/CGP). Data were viewed as PICNIC-segmented
graphical output [43].
Supporting Information
File S1 Figures S1 and S2. Figures S1 and S2 are provided in a
single pdf document. Figure S1. Segmentation by PICNIC
algorithm reveals ‘Parent A’ and ‘Parent B’ origin of segments of
chromosome 13. Figure S2. Pyrosequencing confirmation of the
HSD17B8 mutation.
(PDF)
File S2 Tables S1–S7. Tables provided as a single spreadsheet
in Excel format. Table S1, cytogenetic descriptions of genome
rearrangements in HCC1187, from ref. 12. Table S2, array-CGH
data segmented PICNIC algorithm. Table S3, genome segments
originally identified by array painting in ref. 12, with breakpoints
refined by comparison with array CGH data in table S2. Table S4,
Expressed Fusion Genes. Table S5, Deletions and duplications of
less than 2 Mb, identified from array CGH. Table S6, Sequence-
level mutations, with comments and annotations as described in
the text. Table S7, all genes affected by mutation, with timing,
recurrence of mutation in breast cancer, and brief gene
annotation.
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